Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Gogineni V, et al. Among authors: nemunaitis j. J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406. eCollection 2021. J Cancer. 2021. PMID: 33391401 Free PMC article. Review.
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Oh J, Barve M, Matthews CM, Koon EC, Heffernan TP, Fine B, Grosen E, Bergman MK, Fleming EL, DeMars LR, West L, Spitz DL, Goodman H, Hancock KC, Wallraven G, Kumar P, Bognar E, Manning L, Pappen BO, Adams N, Senzer N, Nemunaitis J. Oh J, et al. Among authors: nemunaitis j. Gynecol Oncol. 2016 Dec;143(3):504-510. doi: 10.1016/j.ygyno.2016.09.018. Epub 2016 Sep 24. Gynecol Oncol. 2016. PMID: 27678295 Clinical Trial.
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
Ghisoli M, Rutledge M, Stephens PJ, Mennel R, Barve M, Manley M, Oliai BR, Murphy KM, Manning L, Gutierrez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J. Ghisoli M, et al. Among authors: nemunaitis j. J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822. J Pediatr Hematol Oncol. 2017. PMID: 28338569
Harnessing the immune response to target tumors.
Manning L, Nemunaitis J. Manning L, et al. Among authors: nemunaitis j. F1000Res. 2017 May 18;6:710. doi: 10.12688/f1000research.10795.1. eCollection 2017. F1000Res. 2017. PMID: 28620466 Free PMC article. Review.
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Metzinger MN, Verghese C, Hamouda DM, Lenhard A, Choucair K, Senzer N, Brunicardi FC, Dworkin L, Nemunaitis J. Metzinger MN, et al. Among authors: nemunaitis j. Oncology. 2019;97(2):59-74. doi: 10.1159/000500488. Epub 2019 Jul 1. Oncology. 2019. PMID: 31261152 Review.
Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.
Ngo N, Choucair K, Creeden JF, Qaqish H, Bhavsar K, Murphy C, Lian K, Albrethsen MT, Stanbery L, Phinney RC, Brunicardi FC, Dworkin L, Nemunaitis J. Ngo N, et al. Among authors: nemunaitis j. Future Oncol. 2019 Nov;15(33):3861-3876. doi: 10.2217/fon-2019-0374. Epub 2019 Oct 31. Future Oncol. 2019. PMID: 31668087 Review.
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
Willis O, Choucair K, Alloghbi A, Stanbery L, Mowat R, Charles Brunicardi F, Dworkin L, Nemunaitis J. Willis O, et al. Among authors: nemunaitis j. Cancer Gene Ther. 2020 Sep;27(9):634-644. doi: 10.1038/s41417-020-0164-0. Epub 2020 Jan 28. Cancer Gene Ther. 2020. PMID: 31988478 Review.
392 results